MovDisordV3, PascalFrancis, Corpus, bibRecord, 001262

Comparison of Desipramine and Citalopram Treatments for Depression in Parkinson's Disease : A Double-Blind, Randomized, Placebo-Controlled Study

Identifieur interne : 001262 ( PascalFrancis/Corpus ); précédent : 001261; suivant : 001263

Comparison of Desipramine and Citalopram Treatments for Depression in Parkinson's Disease : A Double-Blind, Randomized, Placebo-Controlled Study

Auteurs : David Devos ; Kathy Dujardin ; Isabelle Poirot ; Caroline Moreau ; Olivier Cottencin ; Pierre Thomas ; Alain Destee ; Regis Bordet ; Luc Defebvre

Source :

Movement disorders [ 0885-3185 ] ; 2008.

RBID : Pascal:08-0251871

Descripteurs français

Pascal (Inist)
- Etat dépressif, Maladie de Parkinson, Pathologie du système nerveux, Etude comparative, Désipramine, Citalopram, Traitement, Etude double insu, Placebo, Sérotonine, Noradrénaline.

English descriptors

KwdEn :
- Citalopram, Comparative study, Depression, Desipramine, Double blind study, Nervous system diseases, Norepinephrine, Parkinson disease, Placebo, Serotonin, Treatment.

Abstract

Depression is one of the most common psychiatric disturbances in Parkinson's disease (PD). Recent reviews have highlighted the lack of controlled trials and the ensuing difficulty in formulating recommendations for antidepressant use in PD. We sought to establish whether antidepressants provide real benefits and whether tricyclic and selective serotonin reuptake inhibitor (SSRI) antidepressants differ in their short-term efficacy, because the time to onset of therapeutic benefit remains an important criterion in depression. The short-term efficacy (after 14 and 30 days) of two antidepressants (desipramine, a predominantly noradrenergic reuptake inhibitor tricyclic and citalopram, a SSRI) was assessed in a double-blind, randomized, placebo-controlled study of 48 nondemented PD patients suffering from major depression. After 14 days, desipramine prompted an improvement in the Montgomery Asberg Depression Rating Scale (MADRS) score, compared with citalopram and placebo. Both antidepressants produced significant improvements in the MADRS score after 30 days. Mild adverse events were twice as frequent in the desipramine group as in the other groups. A predominantly noradrenergic tricyclic antidepressant induced a more intense short-term effect on parkinsonian depression than did an SSRI. However, desipramine's lower tolerability may outweigh its slight short-term clinical advantage.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 23`
A06				`@2 6`
A08	`01`	`1`	`ENG`	`@1 Comparison of Desipramine and Citalopram Treatments for Depression in Parkinson's Disease : A Double-Blind, Randomized, Placebo-Controlled Study`
A11	`01`	`1`		`@1 DEVOS (David)`
A11	`02`	`1`		`@1 DUJARDIN (Kathy)`
A11	`03`	`1`		`@1 POIROT (Isabelle)`
A11	`04`	`1`		`@1 MOREAU (Caroline)`
A11	`05`	`1`		`@1 COTTENCIN (Olivier)`
A11	`06`	`1`		`@1 THOMAS (Pierre)`
A11	`07`	`1`		`@1 DESTEE (Alain)`
A11	`08`	`1`		`@1 BORDET (Regis)`
A11	`09`	`1`		`@1 DEFEBVRE (Luc)`
A14	`01`			`@1 Department of Neurology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital @2 Lille @3 FRA @Z 1 aut. @Z 2 aut. @Z 4 aut. @Z 7 aut. @Z 9 aut.`
A14	`02`			`@1 Department of Neurophysiology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital @2 Lille @3 FRA @Z 3 aut.`
A14	`03`			`@1 Department of Psychiatry, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital @2 Lille @3 FRA @Z 5 aut. @Z 6 aut.`
A14	`04`			`@1 Department of Pharmacology, IFR 114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital @2 Lille @3 FRA @Z 8 aut.`
A20				`@1 850-857`
A21				`@1 2008`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000195888140120`
A44				`@0 0000 @1 © 2008 INIST-CNRS. All rights reserved.`
A45				`@0 39 ref.`
A47	`01`	`1`		`@0 08-0251871`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Depression is one of the most common psychiatric disturbances in Parkinson's disease (PD). Recent reviews have highlighted the lack of controlled trials and the ensuing difficulty in formulating recommendations for antidepressant use in PD. We sought to establish whether antidepressants provide real benefits and whether tricyclic and selective serotonin reuptake inhibitor (SSRI) antidepressants differ in their short-term efficacy, because the time to onset of therapeutic benefit remains an important criterion in depression. The short-term efficacy (after 14 and 30 days) of two antidepressants (desipramine, a predominantly noradrenergic reuptake inhibitor tricyclic and citalopram, a SSRI) was assessed in a double-blind, randomized, placebo-controlled study of 48 nondemented PD patients suffering from major depression. After 14 days, desipramine prompted an improvement in the Montgomery Asberg Depression Rating Scale (MADRS) score, compared with citalopram and placebo. Both antidepressants produced significant improvements in the MADRS score after 30 days. Mild adverse events were twice as frequent in the desipramine group as in the other groups. A predominantly noradrenergic tricyclic antidepressant induced a more intense short-term effect on parkinsonian depression than did an SSRI. However, desipramine's lower tolerability may outweigh its slight short-term clinical advantage.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Etat dépressif @5 01`
C03	`01`	`X`	`ENG`	`@0 Depression @5 01`
C03	`01`	`X`	`SPA`	`@0 Estado depresivo @5 01`
C03	`02`	`X`	`FRE`	`@0 Maladie de Parkinson @2 NM @5 02`
C03	`02`	`X`	`ENG`	`@0 Parkinson disease @2 NM @5 02`
C03	`02`	`X`	`SPA`	`@0 Parkinson enfermedad @2 NM @5 02`
C03	`03`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 03`
C03	`03`	`X`	`ENG`	`@0 Nervous system diseases @5 03`
C03	`03`	`X`	`SPA`	`@0 Sistema nervioso patología @5 03`
C03	`04`	`X`	`FRE`	`@0 Etude comparative @5 09`
C03	`04`	`X`	`ENG`	`@0 Comparative study @5 09`
C03	`04`	`X`	`SPA`	`@0 Estudio comparativo @5 09`
C03	`05`	`X`	`FRE`	`@0 Désipramine @2 NK @2 FR @5 10`
C03	`05`	`X`	`ENG`	`@0 Desipramine @2 NK @2 FR @5 10`
C03	`05`	`X`	`SPA`	`@0 Desipramina @2 NK @2 FR @5 10`
C03	`06`	`X`	`FRE`	`@0 Citalopram @2 NK @2 FR @5 11`
C03	`06`	`X`	`ENG`	`@0 Citalopram @2 NK @2 FR @5 11`
C03	`06`	`X`	`SPA`	`@0 Citalopram @2 NK @2 FR @5 11`
C03	`07`	`X`	`FRE`	`@0 Traitement @5 12`
C03	`07`	`X`	`ENG`	`@0 Treatment @5 12`
C03	`07`	`X`	`SPA`	`@0 Tratamiento @5 12`
C03	`08`	`X`	`FRE`	`@0 Etude double insu @5 13`
C03	`08`	`X`	`ENG`	`@0 Double blind study @5 13`
C03	`08`	`X`	`SPA`	`@0 Estudio doble ciego @5 13`
C03	`09`	`X`	`FRE`	`@0 Placebo @5 14`
C03	`09`	`X`	`ENG`	`@0 Placebo @5 14`
C03	`09`	`X`	`SPA`	`@0 Placebo @5 14`
C03	`10`	`X`	`FRE`	`@0 Sérotonine @2 NK @2 FR @5 15`
C03	`10`	`X`	`ENG`	`@0 Serotonin @2 NK @2 FR @5 15`
C03	`10`	`X`	`SPA`	`@0 Serotonina @2 NK @2 FR @5 15`
C03	`11`	`X`	`FRE`	`@0 Noradrénaline @2 NK @5 16`
C03	`11`	`X`	`ENG`	`@0 Norepinephrine @2 NK @5 16`
C03	`11`	`X`	`SPA`	`@0 Noradrenalina @2 NK @5 16`
C07	`01`	`X`	`FRE`	`@0 Trouble de l'humeur @5 37`
C07	`01`	`X`	`ENG`	`@0 Mood disorder @5 37`
C07	`01`	`X`	`SPA`	`@0 Trastorno humor @5 37`
C07	`02`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 38`
C07	`02`	`X`	`ENG`	`@0 Cerebral disorder @5 38`
C07	`02`	`X`	`SPA`	`@0 Encéfalo patología @5 38`
C07	`03`	`X`	`FRE`	`@0 Syndrome extrapyramidal @5 39`
C07	`03`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 39`
C07	`03`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 39`
C07	`04`	`X`	`FRE`	`@0 Maladie dégénérative @5 40`
C07	`04`	`X`	`ENG`	`@0 Degenerative disease @5 40`
C07	`04`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 40`
C07	`05`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 41`
C07	`05`	`X`	`ENG`	`@0 Central nervous system disease @5 41`
C07	`05`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 41`
C07	`06`	`X`	`FRE`	`@0 Neurotransmetteur @5 43`
C07	`06`	`X`	`ENG`	`@0 Neurotransmitter @5 43`
C07	`06`	`X`	`SPA`	`@0 Neurotransmisor @5 43`
C07	`07`	`X`	`FRE`	`@0 Catécholamine @5 44`
C07	`07`	`X`	`ENG`	`@0 Catecholamine @5 44`
C07	`07`	`X`	`SPA`	`@0 Catecolamina @5 44`
N21				`@1 162`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 08-0251871 INIST
ET :	Comparison of Desipramine and Citalopram Treatments for Depression in Parkinson's Disease : A Double-Blind, Randomized, Placebo-Controlled Study
AU :	DEVOS (David); DUJARDIN (Kathy); POIROT (Isabelle); MOREAU (Caroline); COTTENCIN (Olivier); THOMAS (Pierre); DESTEE (Alain); BORDET (Regis); DEFEBVRE (Luc)
AF :	Department of Neurology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital/Lille/France (1 aut., 2 aut., 4 aut., 7 aut., 9 aut.); Department of Neurophysiology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital/Lille/France (3 aut.); Department of Psychiatry, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital/Lille/France (5 aut., 6 aut.); Department of Pharmacology, IFR 114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital/Lille/France (8 aut.)
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2008; Vol. 23; No. 6; Pp. 850-857; Bibl. 39 ref.
LA :	Anglais
EA :	Depression is one of the most common psychiatric disturbances in Parkinson's disease (PD). Recent reviews have highlighted the lack of controlled trials and the ensuing difficulty in formulating recommendations for antidepressant use in PD. We sought to establish whether antidepressants provide real benefits and whether tricyclic and selective serotonin reuptake inhibitor (SSRI) antidepressants differ in their short-term efficacy, because the time to onset of therapeutic benefit remains an important criterion in depression. The short-term efficacy (after 14 and 30 days) of two antidepressants (desipramine, a predominantly noradrenergic reuptake inhibitor tricyclic and citalopram, a SSRI) was assessed in a double-blind, randomized, placebo-controlled study of 48 nondemented PD patients suffering from major depression. After 14 days, desipramine prompted an improvement in the Montgomery Asberg Depression Rating Scale (MADRS) score, compared with citalopram and placebo. Both antidepressants produced significant improvements in the MADRS score after 30 days. Mild adverse events were twice as frequent in the desipramine group as in the other groups. A predominantly noradrenergic tricyclic antidepressant induced a more intense short-term effect on parkinsonian depression than did an SSRI. However, desipramine's lower tolerability may outweigh its slight short-term clinical advantage.
CC :	002B17; 002B17G
FD :	Etat dépressif; Maladie de Parkinson; Pathologie du système nerveux; Etude comparative; Désipramine; Citalopram; Traitement; Etude double insu; Placebo; Sérotonine; Noradrénaline
FG :	Trouble de l'humeur; Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du système nerveux central; Neurotransmetteur; Catécholamine
ED :	Depression; Parkinson disease; Nervous system diseases; Comparative study; Desipramine; Citalopram; Treatment; Double blind study; Placebo; Serotonin; Norepinephrine
EG :	Mood disorder; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease; Neurotransmitter; Catecholamine
SD :	Estado depresivo; Parkinson enfermedad; Sistema nervioso patología; Estudio comparativo; Desipramina; Citalopram; Tratamiento; Estudio doble ciego; Placebo; Serotonina; Noradrenalina
LO :	INIST-20953.354000195888140120
ID :	08-0251871

Links to Exploration step

Pascal:08-0251871

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Comparison of Desipramine and Citalopram Treatments for Depression in Parkinson's Disease : A Double-Blind, Randomized, Placebo-Controlled Study</title>
<author><name sortKey="Devos, David" sort="Devos, David" uniqKey="Devos D" first="David" last="Devos">David Devos</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital</s1>
<s2>Lille</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Dujardin, Kathy" sort="Dujardin, Kathy" uniqKey="Dujardin K" first="Kathy" last="Dujardin">Kathy Dujardin</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital</s1>
<s2>Lille</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Poirot, Isabelle" sort="Poirot, Isabelle" uniqKey="Poirot I" first="Isabelle" last="Poirot">Isabelle Poirot</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Neurophysiology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital</s1>
<s2>Lille</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Moreau, Caroline" sort="Moreau, Caroline" uniqKey="Moreau C" first="Caroline" last="Moreau">Caroline Moreau</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital</s1>
<s2>Lille</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Cottencin, Olivier" sort="Cottencin, Olivier" uniqKey="Cottencin O" first="Olivier" last="Cottencin">Olivier Cottencin</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Psychiatry, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital</s1>
<s2>Lille</s2>
<s3>FRA</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Thomas, Pierre" sort="Thomas, Pierre" uniqKey="Thomas P" first="Pierre" last="Thomas">Pierre Thomas</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Psychiatry, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital</s1>
<s2>Lille</s2>
<s3>FRA</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Destee, Alain" sort="Destee, Alain" uniqKey="Destee A" first="Alain" last="Destee">Alain Destee</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital</s1>
<s2>Lille</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bordet, Regis" sort="Bordet, Regis" uniqKey="Bordet R" first="Regis" last="Bordet">Regis Bordet</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Pharmacology, IFR 114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital</s1>
<s2>Lille</s2>
<s3>FRA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Defebvre, Luc" sort="Defebvre, Luc" uniqKey="Defebvre L" first="Luc" last="Defebvre">Luc Defebvre</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital</s1>
<s2>Lille</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">08-0251871</idno>
<date when="2008">2008</date>
<idno type="stanalyst">PASCAL 08-0251871 INIST</idno>
<idno type="RBID">Pascal:08-0251871</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001262</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Comparison of Desipramine and Citalopram Treatments for Depression in Parkinson's Disease : A Double-Blind, Randomized, Placebo-Controlled Study</title>
<author><name sortKey="Devos, David" sort="Devos, David" uniqKey="Devos D" first="David" last="Devos">David Devos</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital</s1>
<s2>Lille</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Dujardin, Kathy" sort="Dujardin, Kathy" uniqKey="Dujardin K" first="Kathy" last="Dujardin">Kathy Dujardin</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital</s1>
<s2>Lille</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Poirot, Isabelle" sort="Poirot, Isabelle" uniqKey="Poirot I" first="Isabelle" last="Poirot">Isabelle Poirot</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Neurophysiology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital</s1>
<s2>Lille</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Moreau, Caroline" sort="Moreau, Caroline" uniqKey="Moreau C" first="Caroline" last="Moreau">Caroline Moreau</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital</s1>
<s2>Lille</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Cottencin, Olivier" sort="Cottencin, Olivier" uniqKey="Cottencin O" first="Olivier" last="Cottencin">Olivier Cottencin</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Psychiatry, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital</s1>
<s2>Lille</s2>
<s3>FRA</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Thomas, Pierre" sort="Thomas, Pierre" uniqKey="Thomas P" first="Pierre" last="Thomas">Pierre Thomas</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Psychiatry, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital</s1>
<s2>Lille</s2>
<s3>FRA</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Destee, Alain" sort="Destee, Alain" uniqKey="Destee A" first="Alain" last="Destee">Alain Destee</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital</s1>
<s2>Lille</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bordet, Regis" sort="Bordet, Regis" uniqKey="Bordet R" first="Regis" last="Bordet">Regis Bordet</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Pharmacology, IFR 114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital</s1>
<s2>Lille</s2>
<s3>FRA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Defebvre, Luc" sort="Defebvre, Luc" uniqKey="Defebvre L" first="Luc" last="Defebvre">Luc Defebvre</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital</s1>
<s2>Lille</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2008">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Citalopram</term>
<term>Comparative study</term>
<term>Depression</term>
<term>Desipramine</term>
<term>Double blind study</term>
<term>Nervous system diseases</term>
<term>Norepinephrine</term>
<term>Parkinson disease</term>
<term>Placebo</term>
<term>Serotonin</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Etat dépressif</term>
<term>Maladie de Parkinson</term>
<term>Pathologie du   système nerveux</term>
<term>Etude comparative</term>
<term>Désipramine</term>
<term>Citalopram</term>
<term>Traitement</term>
<term>Etude double insu</term>
<term>Placebo</term>
<term>Sérotonine</term>
<term>Noradrénaline</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Depression is one of the most common psychiatric disturbances in Parkinson's disease (PD). Recent reviews have highlighted the lack of controlled trials and the ensuing difficulty in formulating recommendations for antidepressant use in PD. We sought to establish whether antidepressants provide real benefits and whether tricyclic and selective serotonin reuptake inhibitor (SSRI) antidepressants differ in their short-term efficacy, because the time to onset of therapeutic benefit remains an important criterion in depression. The short-term efficacy (after 14 and 30 days) of two antidepressants (desipramine, a predominantly noradrenergic reuptake inhibitor tricyclic and citalopram, a SSRI) was assessed in a double-blind, randomized, placebo-controlled study of 48 nondemented PD patients suffering from major depression. After 14 days, desipramine prompted an improvement in the Montgomery Asberg Depression Rating Scale (MADRS) score, compared with citalopram and placebo. Both antidepressants produced significant improvements in the MADRS score after 30 days. Mild adverse events were twice as frequent in the desipramine group as in the other groups. A predominantly noradrenergic tricyclic antidepressant induced a more intense short-term effect on parkinsonian depression than did an SSRI. However, desipramine's lower tolerability may outweigh its slight short-term clinical advantage.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>23</s2>
</fA05>
<fA06><s2>6</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Comparison of Desipramine and Citalopram Treatments for Depression in Parkinson's Disease : A Double-Blind, Randomized, Placebo-Controlled Study</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>DEVOS (David)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>DUJARDIN (Kathy)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>POIROT (Isabelle)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>MOREAU (Caroline)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>COTTENCIN (Olivier)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>THOMAS (Pierre)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>DESTEE (Alain)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>BORDET (Regis)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>DEFEBVRE (Luc)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Neurology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital</s1>
<s2>Lille</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Neurophysiology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital</s1>
<s2>Lille</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Psychiatry, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital</s1>
<s2>Lille</s2>
<s3>FRA</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Department of Pharmacology, IFR 114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital</s1>
<s2>Lille</s2>
<s3>FRA</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA20><s1>850-857</s1>
</fA20>
<fA21><s1>2008</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000195888140120</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2008 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>39 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>08-0251871</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Depression is one of the most common psychiatric disturbances in Parkinson's disease (PD). Recent reviews have highlighted the lack of controlled trials and the ensuing difficulty in formulating recommendations for antidepressant use in PD. We sought to establish whether antidepressants provide real benefits and whether tricyclic and selective serotonin reuptake inhibitor (SSRI) antidepressants differ in their short-term efficacy, because the time to onset of therapeutic benefit remains an important criterion in depression. The short-term efficacy (after 14 and 30 days) of two antidepressants (desipramine, a predominantly noradrenergic reuptake inhibitor tricyclic and citalopram, a SSRI) was assessed in a double-blind, randomized, placebo-controlled study of 48 nondemented PD patients suffering from major depression. After 14 days, desipramine prompted an improvement in the Montgomery Asberg Depression Rating Scale (MADRS) score, compared with citalopram and placebo. Both antidepressants produced significant improvements in the MADRS score after 30 days. Mild adverse events were twice as frequent in the desipramine group as in the other groups. A predominantly noradrenergic tricyclic antidepressant induced a more intense short-term effect on parkinsonian depression than did an SSRI. However, desipramine's lower tolerability may outweigh its slight short-term clinical advantage.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Etat dépressif</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Depression</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Estado depresivo</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Etude comparative</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Comparative study</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Estudio comparativo</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Désipramine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Desipramine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Desipramina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Citalopram</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Citalopram</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Citalopram</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Traitement</s0>
<s5>12</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Treatment</s0>
<s5>12</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>12</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Etude double insu</s0>
<s5>13</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Double blind study</s0>
<s5>13</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Estudio doble ciego</s0>
<s5>13</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Placebo</s0>
<s5>14</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Placebo</s0>
<s5>14</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Placebo</s0>
<s5>14</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Sérotonine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>15</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Serotonin</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>15</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Serotonina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>15</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Noradrénaline</s0>
<s2>NK</s2>
<s5>16</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Norepinephrine</s0>
<s2>NK</s2>
<s5>16</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Noradrenalina</s0>
<s2>NK</s2>
<s5>16</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Trouble de l'humeur</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Mood disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Trastorno humor</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Neurotransmetteur</s0>
<s5>43</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Neurotransmitter</s0>
<s5>43</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Neurotransmisor</s0>
<s5>43</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Catécholamine</s0>
<s5>44</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Catecholamine</s0>
<s5>44</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Catecolamina</s0>
<s5>44</s5>
</fC07>
<fN21><s1>162</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 08-0251871 INIST</NO>
<ET>Comparison of Desipramine and Citalopram Treatments for Depression in Parkinson's Disease : A Double-Blind, Randomized, Placebo-Controlled Study</ET>
<AU>DEVOS (David); DUJARDIN (Kathy); POIROT (Isabelle); MOREAU (Caroline); COTTENCIN (Olivier); THOMAS (Pierre); DESTEE (Alain); BORDET (Regis); DEFEBVRE (Luc)</AU>
<AF>Department of Neurology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital/Lille/France (1 aut., 2 aut., 4 aut., 7 aut., 9 aut.); Department of Neurophysiology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital/Lille/France (3 aut.); Department of Psychiatry, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital/Lille/France (5 aut., 6 aut.); Department of Pharmacology, IFR 114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital/Lille/France (8 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2008; Vol. 23; No. 6; Pp. 850-857; Bibl. 39 ref.</SO>
<LA>Anglais</LA>
<EA>Depression is one of the most common psychiatric disturbances in Parkinson's disease (PD). Recent reviews have highlighted the lack of controlled trials and the ensuing difficulty in formulating recommendations for antidepressant use in PD. We sought to establish whether antidepressants provide real benefits and whether tricyclic and selective serotonin reuptake inhibitor (SSRI) antidepressants differ in their short-term efficacy, because the time to onset of therapeutic benefit remains an important criterion in depression. The short-term efficacy (after 14 and 30 days) of two antidepressants (desipramine, a predominantly noradrenergic reuptake inhibitor tricyclic and citalopram, a SSRI) was assessed in a double-blind, randomized, placebo-controlled study of 48 nondemented PD patients suffering from major depression. After 14 days, desipramine prompted an improvement in the Montgomery Asberg Depression Rating Scale (MADRS) score, compared with citalopram and placebo. Both antidepressants produced significant improvements in the MADRS score after 30 days. Mild adverse events were twice as frequent in the desipramine group as in the other groups. A predominantly noradrenergic tricyclic antidepressant induced a more intense short-term effect on parkinsonian depression than did an SSRI. However, desipramine's lower tolerability may outweigh its slight short-term clinical advantage.</EA>
<CC>002B17; 002B17G</CC>
<FD>Etat dépressif; Maladie de Parkinson; Pathologie du système nerveux; Etude comparative; Désipramine; Citalopram; Traitement; Etude double insu; Placebo; Sérotonine; Noradrénaline</FD>
<FG>Trouble de l'humeur; Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du   système nerveux central; Neurotransmetteur; Catécholamine</FG>
<ED>Depression; Parkinson disease; Nervous system diseases; Comparative study; Desipramine; Citalopram; Treatment; Double blind study; Placebo; Serotonin; Norepinephrine</ED>
<EG>Mood disorder; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease; Neurotransmitter; Catecholamine</EG>
<SD>Estado depresivo; Parkinson enfermedad; Sistema nervioso patología; Estudio comparativo; Desipramina; Citalopram; Tratamiento; Estudio doble ciego; Placebo; Serotonina; Noradrenalina</SD>
<LO>INIST-20953.354000195888140120</LO>
<ID>08-0251871</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001262 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 001262 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:08-0251871
   |texte=   Comparison of Desipramine and Citalopram Treatments for Depression in Parkinson's Disease : A Double-Blind, Randomized, Placebo-Controlled Study
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Comparison of Desipramine and Citalopram Treatments for Depression in Parkinson's Disease : A Double-Blind, Randomized, Placebo-Controlled Study

Comparison of Desipramine and Citalopram Treatments for Depression in Parkinson's Disease : A Double-Blind, Randomized, Placebo-Controlled Study

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri